One year of treatment with the highest dose of the cholesterol-lowering drug rosuvastatin can shrink plaque inside the arteries of patients who have had a certain type of heart attack known as ST-segment elevation myocardial infarction (STEMI), according to a new study presented today at ESC Congress 2014.
BARCELONA, Spain – Tuesday 2 September: One year of treatment with the highest dose of the cholesterol-lowering drug rosuvastatin can shrink plaque inside the arteries of patients who have had a certain type of heart attack known as ST-segment elevation myocardial infarction (STEMI), according to a new study presented today at ESC Congress 2014.Although STEMI patients undergo a revascularisation procedure to unblock the “culprit” artery that caused their heart attack, they remain at increased risk for similar events due to plaque formation in other untreated coronary arteries.The IBIS-4 study, which was published simultaneously in the European Heart Journal is the first to use ultrasound imaging inside coronary arteries both at the time of heart attack and after 13 months of treatment to show the benefit of high-dose statin therapy on plaque burden, said study investigator Lorenz Räber, MD an interventional cardiologist from Bern University Hospital in Bern, Switzerland.The study was an investigator-initiated trial performed at five sites in Europe (University Hospitals of Bern (CH), Copenhagen (DK), Geneva (CH) and Zurich (CH) and Cardiocentro Lugano (CH)) with support from the Swiss National Science Foundation as well as a stent manufacturer (Biosensors SA) and an ultrasound imaging company (Volcano) but without support from a pharmaceutical cholesterol-lowering manufacturer.
“Previous work has shown that high-dose rosuvastatin can reduce plaque size in stable patients, but until now this has not been specifically investigated in arteries of patients with acute heart attacks, a setting known to harbour additional high risk plaques that can be the source for future cardiovascular events,” said Dr. Räber. “Additionally, our study is the first to use intracoronary ultrasound to assess the actual plaque composition and the plaque phenotype, and to observe how both respond to treatment.”
IBIS-4 included 103 acute heart attack patients who were first successfully treated to unblock the culprit vessel. Subjects then underwent imaging, both at the start of the study and then after 13 months of high-intensity rosuvastatin treatment, to assess the drug’s impact on their non-culprit arteries.Rosuvastatin was given at a dose of 40 mg daily. After 13 months, ultrasonography showed that 85% of patients had regression of plaque in at least one artery, and 56% had regression in both. Overall, intracoronary plaque volume was reduced by a mean of -0.9% (p=0.007), with a mean change of the total atheroma volume of -13.7 mm3 (p=0.006). Although the reduction in plaque volume was independent from cholesterol levels at baseline, it was directly related to the extent of cholesterol reduction at 13 months. An analysis of the plaque tissue composition using radiofrequency intravascular ultrasonography showed no changes in high risk tissue (necrotic core) and no reduction in “high risk plaques”.As expected, rosuvastatin also had beneficial effects on cholesterol levels. Low-density lipoprotein (LDL) cholesterol (“bad cholesterol”) decreased from a median of 3.29 mmol/L at baseline to 1.89 mmol/L (p<0.001), corresponding to a 43% reduction. A total of 44% of patients achieved a guideline-recommended LDL level of less than 1.8mmol/L.Professor Stephan Windecker, senior investigator of IBIS-4 at Bern University Hospital, Switzerland noted,
“the beneficial effects of high-dose statin therapy on coronary plaque regression previously observed in patients with stable coronary artery disease can be extended to those at highest risk for cardiovascular complications, namely patients with acute heart attacks. This explains at least in part the clinical benefit of high-dose statin therapy in patients with heart attacks.”
High-dose rosuvastatin (40 mg) is not approved in many European countries. An initial dose of 10-20 mg is usually used.ENDS
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2014The ESC Congress is currently the world's largest international congress in cardiovascular medicine. The spotlight of this year's event is “innovation and the heart”. ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.SOURCES OF FUNDING: The study was funded by a grant from the Swiss National Science Foundation, Biosensors Europe S.A., Morges, Switzerland, and Volcano Cooperation, Belgium. DISCLOSURES: Dr. Räber is the recipient of a research fellowship funded by the Swiss National Science Foundation. The Clinical Trials Unit University of Bern’s Faculty of Medicine, has a staff policy of not accepting honoraria or consultancy fees. Some of the trial investigators report research grants to the institution from Biosensors, Biotronik, Boston Scientific, and Medtronic, and research contracts to the institution from Biotronik, and St Jude.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved